Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach
- PMID: 8022858
- DOI: 10.1016/0163-7258(93)90007-z
Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach
Abstract
A novel, 'double-advantage approach' to developing more effective chemotherapies will be reviewed. This approach is based on a presumption that analogs designed on a sound hypothesis, and combined with a rationally selected drug delivery system, will optimize antitumor activity by creating drugs that are more active and that can be more specifically targeted to tumors. In the design of drugs superior to doxorubicin, we have focused on typical multidrug resistance and new anthracycline analogs, whose uptake is not affected by P-glycoprotein. Analysis of structural elements of anthracyclines affecting activity against multidrug resistant tumors and affinity for liposomes will be discussed. Annamycin, a lipophilic anthracycline analog, was selected for further preclinical development as a liposomal formulation and demonstrated, in the initial biological evaluation, high activity against tumors resistant to doxorubicin.
Similar articles
-
Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.Cancer Res. 1994 Mar 15;54(6):1479-84. Cancer Res. 1994. PMID: 8137251
-
Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.Anticancer Drugs. 1997 Jul;8(6):610-7. doi: 10.1097/00001813-199707000-00009. Anticancer Drugs. 1997. PMID: 9300576
-
Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.Cancer Chemother Pharmacol. 1994;34(2):109-18. doi: 10.1007/BF00685927. Cancer Chemother Pharmacol. 1994. PMID: 8194162
-
[New anthracyclines and multidrug resistance].Haematologica. 1991 Jun;76 Suppl 3:181-3. Haematologica. 1991. PMID: 1752512 Review. Italian. No abstract available.
-
The anthracyclines: will we ever find a better doxorubicin?Semin Oncol. 1992 Dec;19(6):670-86. Semin Oncol. 1992. PMID: 1462166 Review.
Cited by
-
A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.Invest New Drugs. 2007 Aug;25(4):313-26. doi: 10.1007/s10637-007-9053-8. Epub 2007 May 5. Invest New Drugs. 2007. PMID: 17483874
-
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.Int J Nanomedicine. 2006;1(3):297-315. Int J Nanomedicine. 2006. PMID: 17717971 Free PMC article. Review.
-
From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.Mol Nutr Food Res. 2009 Jan;53(1):68-75. doi: 10.1002/mnfr.200700457. Mol Nutr Food Res. 2009. PMID: 19072739 Free PMC article. Review.
-
Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator.Nucleic Acids Res. 2014 May;42(9):6012-24. doi: 10.1093/nar/gku219. Epub 2014 Apr 7. Nucleic Acids Res. 2014. PMID: 24711371 Free PMC article.
-
Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.Invest New Drugs. 2002 Feb;20(1):35-48. doi: 10.1023/a:1014415205955. Invest New Drugs. 2002. PMID: 12003193
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
